A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects
Withdrawn · Phase 1 · NCT06711640
Conditions: Opioid Withdrawal (Disorder), Opioid Use Disorder
At a glance
- Research payments reported, 2025
- $8,575
- U.S. investigators named
- 0
- Sites paid
- 0
About the trial
- Sponsor
- USWM, LLC (dba US WorldMeds) (with National Institute on Drug Abuse (NIDA))
- Tested
- LUCEMYRA (lofexidine) tablets (drug)
- Dates
- Started 2025-06; completion 2026-02
- Results posted
- Not yet
The goal of this clinical study is to evaluate the pharmacokinetic (PK), safety, and tolerability of LUCEMYRA in adolescents age ≥12 to \<18 years old abruptly discontinuing opioid use.
From ClinicalTrials.gov, last updated 2025-08-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Uswm, LLC reported $8,575 in research payments for this study in 2025 (2 payments).
Products named: Lucemyra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $8,575
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.